Brightworth lifted its position in shares of Stryker Corporation (NYSE:SYK) by 2,755.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 41,751 shares of the medical technology company’s stock after acquiring an additional 40,289 shares during the period. Stryker Corporation accounts for 1.4% of Brightworth’s portfolio, making the stock its 14th biggest holding. Brightworth’s holdings in Stryker Corporation were worth $5,930,000 at the end of the most recent reporting period.
Other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. grew its position in Stryker Corporation by 2,526.4% in the 1st quarter. BlackRock Inc. now owns 21,976,771 shares of the medical technology company’s stock valued at $2,893,242,000 after buying an additional 21,140,000 shares in the last quarter. Koch Industries Inc. grew its position in Stryker Corporation by 34,120.3% in the 2nd quarter. Koch Industries Inc. now owns 1,260,675 shares of the medical technology company’s stock valued at $1,252,000 after buying an additional 1,256,991 shares in the last quarter. Vanguard Group Inc. grew its position in Stryker Corporation by 5.2% in the 1st quarter. Vanguard Group Inc. now owns 23,421,053 shares of the medical technology company’s stock valued at $3,083,382,000 after buying an additional 1,161,688 shares in the last quarter. Janus Henderson Group PLC grew its position in Stryker Corporation by 2,237.8% in the 2nd quarter. Janus Henderson Group PLC now owns 1,019,254 shares of the medical technology company’s stock valued at $141,452,000 after buying an additional 975,656 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its position in Stryker Corporation by 41.9% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,403,420 shares of the medical technology company’s stock valued at $184,759,000 after buying an additional 414,715 shares in the last quarter. Institutional investors and hedge funds own 74.00% of the company’s stock.
Shares of Stryker Corporation (NYSE SYK) opened at $156.18 on Friday. The company has a quick ratio of 1.61, a current ratio of 2.37 and a debt-to-equity ratio of 0.63. The stock has a market cap of $58,448.49, a P/E ratio of 24.75, a PEG ratio of 2.46 and a beta of 0.79. Stryker Corporation has a 52-week low of $106.48 and a 52-week high of $160.62.
Stryker Corporation (NYSE:SYK) last posted its quarterly earnings results on Thursday, October 26th. The medical technology company reported $1.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.50 by $0.02. The business had revenue of $3.01 billion during the quarter, compared to analyst estimates of $2.97 billion. Stryker Corporation had a net margin of 14.67% and a return on equity of 24.11%. The firm’s revenue was up 6.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.39 earnings per share. research analysts anticipate that Stryker Corporation will post 6.47 EPS for the current fiscal year.
A number of equities analysts recently issued reports on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Stryker Corporation in a research report on Friday. Oppenheimer Holdings, Inc. set a $156.00 target price on shares of Stryker Corporation and gave the company a “hold” rating in a research report on Monday, October 30th. Cowen and Company set a $166.00 target price on shares of Stryker Corporation and gave the company a “buy” rating in a research report on Sunday, October 29th. Barclays PLC increased their target price on shares of Stryker Corporation from $137.00 to $148.00 and gave the company an “underweight” rating in a research report on Friday, October 27th. Finally, Canaccord Genuity increased their target price on shares of Stryker Corporation from $155.00 to $162.00 and gave the company a “buy” rating in a research report on Friday, October 27th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and twelve have issued a buy rating to the company. Stryker Corporation has a consensus rating of “Hold” and a consensus price target of $151.52.
COPYRIGHT VIOLATION WARNING: “Brightworth Purchases 40,289 Shares of Stryker Corporation (SYK)” was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.com-unik.info/2017/11/05/brightworth-purchases-40289-shares-of-stryker-corporation-syk.html.
In other news, insider Graham A. Mclean sold 1,124 shares of the stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $146.26, for a total value of $164,396.24. Following the completion of the sale, the insider now directly owns 8,983 shares of the company’s stock, valued at $1,313,853.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 7.40% of the stock is owned by corporate insiders.
Stryker Corporation Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
What are top analysts saying about Stryker Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Stryker Corporation and related companies.